Loading...

DocCheck AG

AJ91.DEXETRA
Healthcare
Medical - Healthcare Information Services
12.60
0.10(0.80%)
German Market opens in 41h 31m

DocCheck AG Fundamental Analysis

DocCheck AG (AJ91.DE) shows moderate financial fundamentals with a PE ratio of 11.98, profit margin of 9.53%, and ROE of 13.28%. The company generates $0.1B in annual revenue with weak year-over-year growth of 0.69%.

Key Strengths

Cash Position29.00%
PEG Ratio0.12
Current Ratio3.18

Areas of Concern

No major concerns flagged.
We analyze AJ91.DE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 50.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
50.8/100

We analyze AJ91.DE's fundamental strength across five key dimensions:

Efficiency Score

Weak

AJ91.DE struggles to generate sufficient returns from assets.

ROA > 10%
9.58%

Valuation Score

Excellent

AJ91.DE trades at attractive valuation levels.

PE < 25
11.98
PEG Ratio < 2
0.12

Growth Score

Weak

AJ91.DE faces weak or negative growth trends.

Revenue Growth > 5%
0.69%
EPS Growth > 10%
1.31%

Financial Health Score

Excellent

AJ91.DE maintains a strong and stable balance sheet.

Debt/Equity < 1
0.10
Current Ratio > 1
3.18

Profitability Score

Weak

AJ91.DE struggles to sustain strong margins.

ROE > 15%
13.28%
Net Margin ≥ 15%
9.53%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is AJ91.DE Expensive or Cheap?

P/E Ratio

AJ91.DE trades at 11.98 times earnings. This suggests potential undervaluation.

11.98

PEG Ratio

When adjusting for growth, AJ91.DE's PEG of 0.12 indicates potential undervaluation.

0.12

Price to Book

The market values DocCheck AG at 1.54 times its book value. This may indicate undervaluation.

1.54

EV/EBITDA

Enterprise value stands at 6.53 times EBITDA. This is generally considered low.

6.53

How Well Does AJ91.DE Make Money?

Net Profit Margin

For every $100 in sales, DocCheck AG keeps $9.53 as profit after all expenses.

9.53%

Operating Margin

Core operations generate 14.72 in profit for every $100 in revenue, before interest and taxes.

14.72%

ROE

Management delivers $13.28 in profit for every $100 of shareholder equity.

13.28%

ROA

DocCheck AG generates $9.58 in profit for every $100 in assets, demonstrating efficient asset deployment.

9.58%

Following the Money - Real Cash Generation

Operating Cash Flow

DocCheck AG produces operating cash flow of $5.95M, showing steady but balanced cash generation.

$5.95M

Free Cash Flow

DocCheck AG produces free cash flow of $2.42M, offering steady but limited capital for shareholder returns and expansion.

$2.42M

FCF Per Share

Each share generates $0.48 in free cash annually.

$0.48

FCF Yield

AJ91.DE converts 3.79% of its market value into free cash.

3.79%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

11.98

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.12

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.54

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.14

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.18

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.13

vs 25 benchmark

ROA

Return on assets percentage

0.10

vs 25 benchmark

ROCE

Return on capital employed

0.18

vs 25 benchmark

How AJ91.DE Stacks Against Its Sector Peers

MetricAJ91.DE ValueSector AveragePerformance
P/E Ratio11.9828.81 Better (Cheaper)
ROE13.28%643.00% Weak
Net Margin9.53%-44312.00% (disorted) Weak
Debt/Equity0.100.36 Strong (Low Leverage)
Current Ratio3.184.50 Strong Liquidity
ROA9.58%-17799.00% (disorted) Weak

AJ91.DE outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews DocCheck AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

63.64%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

65.49%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

322.40%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ